Paul A Carpenter

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease
    Yoshihiro Inamoto
    Haematologica 99:385-91. 2014
  2. ncbi request reprint A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
    Paul A Carpenter
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, USA
    Blood 99:2712-9. 2002
  3. doi request reprint Late effects of chronic graft-versus-host disease
    Paul A Carpenter
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Mailstop D5 290, Seattle, WA 98107, USA
    Best Pract Res Clin Haematol 21:309-31. 2008
  4. ncbi request reprint Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease
    Paul A Carpenter
    Fred Hutchinson CRC, Seattle, Washington, USA
    Biol Blood Marrow Transplant 13:683-90. 2007
  5. pmc Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia
    Paul A Carpenter
    Clinical Research Division, Fred Hutchinson Cancer Research Center FHCRC, Seattle, WA 98109, USA
    Blood 109:2791-3. 2007
  6. pmc Management of acute graft-versus-host disease in children
    Paul A Carpenter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Mailstop D5 290, Seattle, WA 98109, USA
    Pediatr Clin North Am 57:273-95. 2010
  7. ncbi request reprint A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease
    Paul A Carpenter
    Fred Hutchinson Cancer Research Center, Clinical Research Division, 1100 Fairview Ave N, Mailstop D5 290, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 11:465-71. 2005
  8. doi request reprint How I conduct a comprehensive chronic graft-versus-host disease assessment
    Paul A Carpenter
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 118:2679-87. 2011
  9. pmc A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington, USA
    Biol Blood Marrow Transplant 17:1088-92. 2011
  10. pmc Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study
    Fabrizio Carnevale-Schianca
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 15:749-56. 2009

Detail Information

Publications42

  1. pmc Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease
    Yoshihiro Inamoto
    Haematologica 99:385-91. 2014
    ..Our results support the use of complete or very good partial response at day 28 as an appropriate short-term primary endpoint. ..
  2. ncbi request reprint A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
    Paul A Carpenter
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, USA
    Blood 99:2712-9. 2002
    ..Visilizumab is well tolerated and has activity in advanced GVHD. A phase 2 study incorporating preemptive therapy for PTLD is warranted to determine the efficacy of visilizumab in GVHD...
  3. doi request reprint Late effects of chronic graft-versus-host disease
    Paul A Carpenter
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Mailstop D5 290, Seattle, WA 98107, USA
    Best Pract Res Clin Haematol 21:309-31. 2008
    ..Almost all organ systems may be involved, and a broad approach is needed to allow recognition and anticipation of problems so that prevention or early intervention is possible...
  4. ncbi request reprint Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease
    Paul A Carpenter
    Fred Hutchinson CRC, Seattle, Washington, USA
    Biol Blood Marrow Transplant 13:683-90. 2007
    ..12 (-2.28 to +4.24) among the controls and +1.43 (-0.29 to +3.72) for the bisphosphonate group (P = .0002). The greatest improvement in BMD was observed in children who received therapy with bisphosphonates...
  5. pmc Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia
    Paul A Carpenter
    Clinical Research Division, Fred Hutchinson Cancer Research Center FHCRC, Seattle, WA 98109, USA
    Blood 109:2791-3. 2007
    ..We conclude that imatinib can be safely administered early after myeloablative allogeneic HCT at a dose intensity comparable to that used in primary therapy...
  6. pmc Management of acute graft-versus-host disease in children
    Paul A Carpenter
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Mailstop D5 290, Seattle, WA 98109, USA
    Pediatr Clin North Am 57:273-95. 2010
    ..This article reviews the clinical presentation, treatment, and practical management guidelines for children with aGVHD...
  7. ncbi request reprint A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease
    Paul A Carpenter
    Fred Hutchinson Cancer Research Center, Clinical Research Division, 1100 Fairview Ave N, Mailstop D5 290, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 11:465-71. 2005
    ..Survival at 180 days was 32% (95% confidence interval, 18%-46%). The administration of visilizumab as used in this study seems to be sufficiently safe and effective to warrant further assessment for treatment or prevention of GVHD...
  8. doi request reprint How I conduct a comprehensive chronic graft-versus-host disease assessment
    Paul A Carpenter
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 118:2679-87. 2011
    ..This article tries to address many of these issues by describing how I conduct a comprehensive cGVHD assessment using a streamlined and reliable method that I use regularly within the constraints of a busy clinic...
  9. pmc A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington, USA
    Biol Blood Marrow Transplant 17:1088-92. 2011
    ..A larger registry study should be performed to provide more definitive information comparing outcomes with the 2 calcineurin inhibitors...
  10. pmc Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study
    Fabrizio Carnevale-Schianca
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 15:749-56. 2009
    ..The difficulty of demonstrating clinical benefits from objective parameters, such as survival and morbidity, and the subjectivity of grading acute GVHD emphasize the need for blinded assessments in clinical trials of GVHD prevention...
  11. pmc Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors
    Terry Furlong
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 14:531-7. 2008
    ..In these studies, the addition of sirolimus to regimens containing a calcineurin inhibitor and methotrexate appeared to cause toxicity and provided no detectable improvement in preventing GVHD...
  12. pmc Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 121:5098-103. 2013
    ..We found a substantial incidence of sclerosis in patients with chronic GVHD. Development of sclerosis can cause disability but does not affect mortality or recurrent malignancy in patients with chronic GVHD...
  13. pmc Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 118:456-63. 2011
    ..In patients without GVHD, early withdrawal of IST might help to prevent relapse during the first 18 months, but other interventions would be needed to prevent relapse at later time points...
  14. pmc Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:2888-94. 2009
    ..We conclude that initial treatment with low-dose glucocorticoids for patients with grades I-II GVHD did not compromise disease control or mortality and was associated with decreased toxicity...
  15. pmc Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria
    Mary E D Flowers
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA and
    Blood 117:3214-9. 2011
    ..These results suggest that the mechanisms involved in acute and chronic GVHD are not entirely congruent and that chronic GVHD is not simply the end stage of acute GVHD...
  16. pmc Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 121:2340-6. 2013
    ..These success rates could be used as the basis for a clinically relevant and efficient shorter-term end point in clinical studies that evaluate agents for second-line systemic treatment of chronic GVHD...
  17. pmc Clinical benefit of response in chronic graft-versus-host disease
    Yoshihiro Inamoto
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Electronic address
    Biol Blood Marrow Transplant 18:1517-24. 2012
    ..Modification of the algorithm or validation of other more meaningful clinical endpoints is warranted for future clinical trials of treatment for chronic graft-versus-host disease...
  18. pmc Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation
    Nandita Khera
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Clin Oncol 30:71-7. 2012
    ..Our objective was to describe the incidence of nonmalignant late complications and their association with health and functional status in a recent cohort of hematopoietic cell transplantation (HCT) survivors...
  19. pmc Assessment of joint and fascia manifestations in chronic graft-versus-host disease
    Yoshihiro Inamoto
    Fred Hutchinson Cancer Research Center, Seattle, Washington
    Arthritis Rheumatol 66:1044-52. 2014
    ....
  20. doi request reprint Relationship of body mass index and arm anthropometry to outcomes after pediatric allogeneic hematopoietic cell transplantation for hematologic malignancies
    Paul A Hoffmeister
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Biol Blood Marrow Transplant 19:1081-6. 2013
    ..Anthropometry variables were not associated with acute or chronic GVHD. In conclusion, arm muscle area <5th percentile appears to be a stronger predictor than BMI of poor outcomes after HCT in children with hematologic malignancies...
  21. ncbi request reprint Duration of immunosuppressive treatment for chronic graft-versus-host disease
    Betty L Stewart
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, PO Box 19024, Seattle, WA 98109, USA
    Blood 104:3501-6. 2004
    ..After the dose of prednisone was taken into account, progressive onset was not associated with an increased risk of nonrelapse mortality...
  22. pmc Success of allogeneic marrow transplantation for children with severe aplastic anaemia
    LAURI M BURROUGHS
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Br J Haematol 158:120-8. 2012
    ..These results confirm the use of allogeneic marrow transplantation for children with SAA who have HLA-matched related donors...
  23. pmc Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 17:124-32. 2011
    ....
  24. pmc Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia
    Jean E Sanders
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 118:1421-8. 2011
    ..These data indicate that the majority of long-term survivors after transplantation for AA during childhood can have a normal productive life...
  25. pmc Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease
    Paul J Martin
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:5074-82. 2009
    ..9-4.3) among patients in the MMF arm compared with the control arm. MMF should not be added to the initial systemic treatment regimen for chronic GVHD. This trial was registered at www.clinicaltrials.gov as #NCT00089141 on August 4, 2004...
  26. pmc Thyroid function following hematopoietic cell transplantation in children: 30 years' experience
    Jean E Sanders
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:306-8. 2009
    ..008). Thyroid tumors occurred at a median of 9.9 (4.5-22.3) years after HCT and included 13 with papillary carcinoma and 5 with benign adenomas. Children who receive a HCT should be monitored for thyroid abnormalities throughout life...
  27. pmc Secondary treatment of acute graft-versus-host disease: a critical review
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:982-8. 2012
    ..Adherence to the proposed criteria in future reports would enable meaningful comparisons across studies and thereby accelerate progress in evaluating new treatments for patients with aGVHD...
  28. pmc Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome
    LAURI M BURROUGHS
    Fred Hutchinson Cancer Research Center, Seattle, Wash 98109 1024, USA
    J Allergy Clin Immunol 126:1000-5. 2010
    ..Hematopoietic cell transplantation is currently the only viable option for long-term survival, but patients are frequently very ill and may not tolerate traditional myeloablative conditioning regimens...
  29. pmc First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation
    Paul J Martin
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:1150-63. 2012
    ..Because the literature provides little basis for a definitive guideline, this review also provides a framework for the interpretation of previous results and the design of future studies...
  30. ncbi request reprint Steroid-refractory graft-vs.-host disease: past, present and future
    Paul A Carpenter
    Fred Hutchinson Cancer Research Center and University of Washington, Department of Pediatrics, Seattle, WA 98109, USA
    Pediatr Transplant 7:19-31. 2003
    ..Co-operative studies are necessary to hasten the process of evaluating novel treatment strategies for acute and chronic GVHD...
  31. pmc Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia
    Jean E Sanders
    Fred Hutchinson Cancer Research Center, Clinical Research Division, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 105:3749-56. 2005
    ..Late effects included growth and other hormone deficiencies. These data demonstrate that infants with ALL and MLL gene have excellent DFS when they received transplants in CR1, and consideration for transplantation in CR1 is warranted...
  32. ncbi request reprint Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia
    Soheil Meshinchi
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 9:706-13. 2003
    ..Because a higher tumor burden at the time of second HSCT was associated with a higher risk of subsequent relapse, patients might benefit from reinduction therapy before the second HSCT...
  33. pmc Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation
    Stephanie J Lee
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 15:416-20. 2009
    ..Longer follow-up is needed to determine whether early detection and intervention affect later morbidity and mortality...
  34. ncbi request reprint Diagnosis and clinical management of chronic graft-versus-host disease
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, D2 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Int J Hematol 79:221-8. 2004
    ..The remaining 40% die or develop recurrent malignancy before the chronic GVHD resolves. An improved understanding of the pathogenesis of the disease is needed to develop more effective therapy...
  35. pmc Validation of measurement scales in ocular graft-versus-host disease
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Ophthalmology 119:487-93. 2012
    ..Candidate scales were recommended for use in clinical trials by the National Institutes of Health (NIH) Chronic GVHD Consensus Conference or have been previously validated in dry eye syndromes...
  36. ncbi request reprint Final adult height of patients who received hematopoietic cell transplantation in childhood
    Jean E Sanders
    Clinical Research Division, Fred Hutchinson Cancer Research Center, D5 280, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 105:1348-54. 2005
    ..02) also showed more rapid growth than their counterparts. These data demonstrate that GH therapy improves the final height of young children after fractionated TBI...
  37. ncbi request reprint Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease
    Terry Furlong
    Fred Hutchinson Cancer Research Center, and the Department of Medicine, University of Washington, Seattle 98109 1024, USA
    Biol Blood Marrow Transplant 8:206-12. 2002
    ..Fifty-three patients (51%) remain alive at 129-1883 days after transplantation. These results suggest that PUVA can be an effective therapy for steroid-resistant acute GVHD of the skin...
  38. pmc Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease
    Kikuchi Takahide
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 13:1016-21. 2007
    ..0) after SL fitting. Disability related to KCS resolved in 7 patients after SL fitting. The use of SL appears to be safe and effective in patients with severe cGVHD-related KCS refractory to conventional therapies...
  39. pmc Treatment of chronic graft-versus-host disease: Past, present and future
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Korean J Hematol 46:153-63. 2011
    ..Improved treatments are more likely to emerge if reviewers and journal editors hold authors to higher standards in evaluating manuscripts for publication...
  40. ncbi request reprint Activation of occult hepatitis B from a seronegative patient after hematopoietic cell transplant: a cautionary tale
    Paul A Carpenter
    Blood 99:4245-6. 2002
  41. ncbi request reprint Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working
    Daniel Couriel
    University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Biol Blood Marrow Transplant 12:375-96. 2006
    ..Optimal care of patients with chronic GVHD often requires a multidisciplinary approach...
  42. ncbi request reprint Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease
    Paul A Carpenter
    Biol Blood Marrow Transplant 12:792-4. 2006